{"id":140768,"date":"2023-02-09T10:59:32","date_gmt":"2023-02-09T15:59:32","guid":{"rendered":"https:\/\/44.250.171.167\/?p=140768"},"modified":"2023-02-14T03:55:02","modified_gmt":"2023-02-14T08:55:02","slug":"earnings-summary-of-gland-pharma-for-q3-fy23","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/earnings-summary-of-gland-pharma-for-q3-fy23\/","title":{"rendered":"Earnings Summary Of Gland Pharma For Q3 FY23"},"content":{"rendered":"

Gland Pharma Limited<\/a> (NSE: GLAND<\/a>) is an Indian pharmaceutical company that specialises in producing high-quality, low-cost generic medications. The company has a broad range of products and is expanding its presence in both domestic and foreign markets.<\/p>\n

In terms of earnings, Revenue from Operations for Q3 FY23 was \u20b9938.28 crore, a 12% decrease from \u20b91,063.32 crore in the same period last year. The core markets of the company – the US, Canada, Europe, Australia, and New Zealand, generated a total of 662.6 Crore in revenue, or 70% of the total. The core market segment fell by 11% from the previous year down to \u20b9740.6 Crore. The supply chain issues had an effect on this market. The management is making an effort to increase material accessibility and address any production delays.<\/p>\n

The India market accounts for 9% of revenue in Q3 FY23. A total of \u20b981.4 Crore were contributed by the domestic market, a sharp decline of 32% from the same quarter last year. Sales and margins for the India business have been impacted by both the recent publication of the NLEM list and the significant price reductions announced for key products like Heparin. The Rest of the World market, which reported revenue of \u20b9194.3 Crore, accounted for the remaining 21% of the overall Revenue.<\/p>\n

The Consolidated Net Profit was \u20b9231.94 crore, down 15% from \u20b9273.02 crore in the same quarter last year. A higher depreciation expense on the company’s newly capitalised assets had an effect on profit. This quarter’s earnings per share was \u20b914.08.<\/p>\n

The third quarter’s other income, which came from operating gains and interest on fixed deposits, totalled \u20b961.5 Crore. In the same time period, the company’s EBITDA margin was 35% and its net profit margin was 23%. As of December 31, 2022, it had a Cash & Bank balance of $3,829 Crore, demonstrating its ability to maintain a strong cash position. This should give the business the financial freedom to invest in potential areas of future expansion. Additionally, in Q3 FY23, the company produced cash flow from operations of \u20b939.8 Crore.<\/p>\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure>\n","protected":false},"excerpt":{"rendered":"

Gland Pharma Limited (NSE: GLAND) is an Indian pharmaceutical company that specialises in producing high-quality, low-cost generic medications. The company has a broad range of products and is expanding its presence in both domestic and foreign markets. In terms of earnings, Revenue from Operations for Q3 FY23 was \u20b9938.28 crore, a 12% decrease from \u20b91,063.32 […]<\/p>\n","protected":false},"author":1917,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392],"tags":[1115],"class_list":["post-140768","post","type-post","status-publish","format-standard","hentry","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":138943,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-limited-q3-fy23-net-profit-down-to-232-crore\/","url_meta":{"origin":140768,"position":0},"title":"Gland Pharma Limited Q3 FY23; Net Profit Down To 232 Crore","author":"Hardik Bhandare","date":"January 23, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) reported Revenue from Operations of \u20b9938.28 Crore down from \u20b91,063.32 Crore year on year, a decline of 11.8%. Consolidated Net Profit of \u20b9231.94 Crore, slumped 15% from \u20b9273 Crore in the same quarter of the previous year. The Earnings per Share is \u20b914.08 for this\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/9b26cddc-4495-478c-ae9c-1d0e483d0b54-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":146646,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-gland-pharma-limited-for-q4-fy23\/","url_meta":{"origin":140768,"position":1},"title":"Earnings Summary Of Gland Pharma Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 18, 2023","format":false,"excerpt":"Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company's focus on sterile injectables positions it as a key player in critical care, oncology, ophthalmology, and other therapeutic areas. Gland Pharma's state-of-the-art manufacturing facilities adhere to international quality standards,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-4-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":140762,"url":"https:\/\/alphastreet.com\/india\/gland-pharmas-acquisition-of-cenexi-decline-in-lead-products-market-share\/","url_meta":{"origin":140768,"position":2},"title":"Gland Pharma\u2019s Acquisition Of Cenexi & Decline In Lead Product\u2019s Market Share","author":"Hardik Bhandare","date":"February 9, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) is a major player in the Indian pharmaceutical market, specialising in the production and sale of generic injectable pharmaceuticals. It was founded in 1978 and went public in November 2020. The company's products are used in a wide range of therapeutic areas, including oncology, critical\u2026","rel":"","context":"In "Analysis"","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":178326,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":140768,"position":3},"title":"Gland Pharma Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of \u20b91,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to \u20b9261 crore. Total expenses increased 20.03% YoY to \u20b91,372 crore, reflecting strong revenue growth with controlled cost escalation. Revenue & Growth Revenues grew to \u20b91,695.00 crore in Q3FY26 from\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172096,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":140768,"position":4},"title":"Gland Pharma\u00a0Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 4, 2025","format":false,"excerpt":"Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets. Financial Highlights: Revenues increased 5.76% year on year to \u20b91,487 crore from \u20b91,406 crore. Total expenses rose 6.45% to \u20b91,287 crore from \u20b91,209 crore. Consolidated net profit rose\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170073,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":140768,"position":5},"title":"Gland Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 12, 2025","format":false,"excerpt":"Gland Pharma Limited, established in Hyderabad, India in 1978, has evolved from being a contract manufacturer of small-volume liquid parenteral products to becoming one of the largest and fastest-growing injectable-focused companies in the world. With a presence in over 60 countries\u2014including the United States, Europe, Canada, Australia, and India\u2014the company\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"GLAND Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1917"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=140768"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/140768\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=140768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=140768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=140768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}